Search results
Results from the WOW.Com Content Network
A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to schizophrenia treatment. The Food and Drug Administration approved it Thursday.
Sept. 27, 2024 – In a breakthrough for people living with schizophrenia, the FDA has approved a new oral medication for adults. Unlike traditional antipsychotic drugs, the medication, which will be...
Today, the U.S. Food and Drug Administration approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. It is the first...
The FDA has approved Cobenfy, the first new schizophrenia treatment in over 30 years. Cobenfy helps reduce both positive and negative schizophrenia symptoms, with side effects compared to current medications.
The Food and Drug Administration, as expected, approved KarXT, the first new type of drug for schizophrenia in decades. It appears to be effective, but its main advantage is milder side...
N o new treatments for schizophrenia have been approved in nearly three decades, but that changed on Sept. 26, when the U.S. Food and Drug Administration (FDA) approved Cobenfy for the...
The Food and Drug Administration on Thursday approved the first novel antipsychotic treatment in decades, a drug developed to treat schizophrenia without disabling side effects like weight gain....
Now, a new combination drug called Cobenfy has been approved by the US Food and Drug Administration (FDA). It is the first new pharmacological approach for treating schizophrenia in over 50 years and may provide an alternative option for people living with the condition.
The fixed-dose combination of xanomeline and trospium is the first drug to provide a new mechanism of action in over 70 years for the psychiatric disorder, at last expanding the...
The US Food and Drug Administration (FDA) has approved xanomeline and trospium chloride capsules (Cobenfy) for the treatment of schizophrenia in adults. The drug is the first antipsychotic treatment with a novel mode of action to be approved for the condition in more than 50 years.